0000950170-24-063974.txt : 20240523 0000950170-24-063974.hdr.sgml : 20240523 20240523162528 ACCESSION NUMBER: 0000950170-24-063974 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240523 FILED AS OF DATE: 20240523 DATE AS OF CHANGE: 20240523 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bruno Julianne CENTRAL INDEX KEY: 0002019645 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 24978672 MAIL ADDRESS: STREET 1: C/O CRISPR THERAPEUTICS STREET 2: 105 WEST FIRST STREET CITY: BOSTON STATE: MA ZIP: 02127 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 3 1 ownership.xml 3 X0206 3 2024-05-23 0 0001674416 CRISPR Therapeutics AG CRSP 0002019645 Bruno Julianne C/O CRISPR THERAPEUTICS 105 WEST FIRST STREET BOSTON MA 02127 false true false false Chief Operating Officer Common Shares 3111 D Common Shares 7088 I By Julianne Bruno 2022 GRAT Stock Option (Right to Buy) 38.82 2029-05-01 Common Shares 10000 D Stock Option (Right to Buy) 39 2029-10-22 Common Shares 2200 D Stock Option (Right to Buy) 44.67 2030-03-10 Common Shares 3105 D Stock Option (Right to Buy) 86.75 2030-10-05 Common Shares 1800 D Stock Option (Right to Buy) 133.88 2031-03-11 Common Shares 4719 D Stock Option (Right to Buy) 97 2031-10-15 Common Shares 1966 D Stock Option (Right to Buy) 58.29 2032-02-18 Common Shares 6000 D Stock Option (Right to Buy) 61.65 2032-10-07 Common Shares 4000 D Stock Option (Right to Buy) 43.22 2033-03-10 Common Shares 15333 D Stock Option (Right to Buy) 44.31 2033-10-13 Common Shares 10000 D Stock Option (Right to Buy) 72.94 2034-03-20 Common Shares 20000 D Restricted Stock Units Common Shares 435 D Restricted Stock Units Common Shares 7000 D Restricted Stock Units Common Shares 1300 D Restricted Stock Units Common Shares 8500 D Restricted Stock Units Common Shares 7195 D Restricted Stock Units Common Shares 20000 D Restricted Stock Units Common Shares 15000 D Shares held by Julianne Bruno 2022 GRAT, a grantor retained annuity trust of which the Reporting Person's spouse serves as trustee. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein, if any. This option was granted on May 1, 2019 with respect to 10,000 Common Shares. 25% of the shares vested on May 1, 2020, with the remaining shares vested in 36 equal monthly installments thereafter. This option was granted on October 22, 2019 with respect to 2,200 Common Shares. 100% of the shares vested in 48 equal monthly installments, with the first installment vested on November 22, 2019. This option was granted on March 10, 2020 with respect to 3,105 Common Shares. 100% of the shares vested in 48 equal monthly installments, with the first installment vested on April 10, 2020. This option was granted on October 5, 2020 with respect to 1,800 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on November 5, 2020. This option was granted on March 11, 2021 with respect to 4,719 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on April 11, 2021. This option was granted on October 15, 2021 with respect to 1,966 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on November 15, 2021. This option was granted on February 18, 2022 with respect to 6,000 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on March 18, 2022. This option was granted on October 7, 2022 with respect to 4,000 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on November 7, 2022. This option was granted on March 10, 2023 with respect to 15,333 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on April 10, 2023. This option was granted on October 13, 2023 with respect to 10,000 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on November 13, 2023. This option was granted on March 20, 2024 with respect to 20,000 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on April 20, 2024. This restricted stock unit award was granted on March 11, 2021 with respect to 1,740 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. This restricted stock unit award was granted on December 14, 2021 with respect to 7,000 Common Shares, with 100% of the shares vesting on June 20, 2024. This restricted stock unit award was granted on February 18, 2022 with respect to 2,600 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. This restricted stock unit award was granted on December 22, 2022 with respect to 8,500 Common Shares, with 100% of the shares vesting on June 22, 2025. This restricted stock unit award was granted on March 10, 2023 with respect to 9,593 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027. This restricted stock unit award was granted on September 15, 2023 with respect to 20,000 Common Shares, with 100% of the shares vesting on September 15, 2025. This restricted stock unit award was granted on March 20, 2024 with respect to 15,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. Exhibit 24 - Power of Attorney /s/ Julianne Bruno 2024-05-23 EX-24 2 crsp-ex24.htm EX-24 EX-24

POWER OF ATTORNEY

 

Know all by these presents, that the undersigned hereby constitutes and appoints each of James R. Kasinger, Elizabeth Ryland Waldinger, AJ Silver and Robert E. Puopolo, signing singly, the undersigned’s true and lawful attorney-in-fact to:

 

(1) execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of CRISPR Therapeutics AG (the “Company”), (i) Form ID, including any attached documents, to effect the assignment of codes to the undersigned to be used in the transmission of information to the United States Securities and Exchange Commission using the EDGAR System, and (ii) Forms 3, 4 and 5 and amendments thereto in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;

 

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and amendments thereto and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

 

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended. The undersigned hereby agrees to indemnify the attorney-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to the attorney-in-fact.

 

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney may be filed with the United States Securities and Exchange Commission as a confirming statement of the authority granted herein. This Power of Attorney supersedes any prior power of attorney in connection with the undersigned’s capacity as an officer and/or director of the Company. This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to be an executive officer of, or legal counsel to the Company.

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of May 23, 2024.

 

/s/ Julianne Bruno

Signature

 

 

 

Julianne Bruno

Print Name